中国骨伤2025，Vol.38Issue(12)：1194-1200,7.DOI:10.12200/j.issn.1003-0034.20250554
祛浊通痹方联合非布司他治疗痛风间歇期的队列研究
A cohort study on treatment of intermission period of gout with Quzhuo Tongbi formula(祛浊通痹方)combined with febuxostat
摘要
Abstract
Objective To explore efficacy and safety of Quzhuo Tongbi formula(祛 浊通痹方)combined with febustat in treating interlude period of gout(spleen deficiency and dampness obstruction type).Methods From July 2024 to April 2025,102 patients with gout during intermission period were selected for a cohort study and divided into Western medicine group and Chinese and Western group.There were 51 male patients in Western medicine group,aged with an age of(43.59±12.18)years old and the average courses of disease was(91.04±82.26)months.There were 51 patients in Chinese and West-ern group,including 49 males and 2 females with an average age of(47.67±11.75)years old,and the average course of disease was(92.41±85.92)months.The Western medicine group was took febuxotropic orally,while Chinese and Western medicine group was took Quzhuo Tongbi formula(祛浊通痹方)combined with febuxotropic orally,12 weeks constituted as 1 course of treatment,and both groups were treated for 1 course in totally.The changes of serum uric acid(SUA),total cholesterol(TC),and triglycerides(TG),low-density lipoprotein(LDL),alanine aminotransferase(ALT),aspartate aminotransferase(AST),serum creatinine(Scr),and blood urea nitrogen(BUN)between two groups before and after treatment were detected and com-pared;numeric rating scale(NRS),patient global assessment(PGA),and TCM syndrome scores before and after treatment were compared;the number of gout attacks within 12 weeks and adverse reactions during treatment process were recorded.Re-sults Totally 99 patients were finally observed clinically,including 50 patients in Western group and 49 patients in Chinese and Western groups.After 12 weeks of treatment,the indicators such as SUA,Scr and BUN in Western medicine group were de-creased compared with those of before treatment(P＜0.01),and the indicators such as SUA,TC,TG,LDL,ALT,AST,Scr and BUN in Chinese and Western medicine group were decreased significantly compared with those of before treatment(P＜0.05).Moreover,the improvement of indicators such as SUA,LDL,ALT,AST,and Scr in Chinese and Western medicine group were better than those of in Western medicine group(P＜0.05).During the treatment period,the frequency of gout attacks in Chinese and Western medicine group was lower than that in Western medicine group(P＜0.01).The NRS,PGA scores and TCM syn-drome scores of both groups were decreased compared with those of before treatment(P＜0.01),and the improvement of NRS and PGA scores in Chinese and Western medicine group were better than those of in Western medicine group(P＜0.01).One patient developed liver function damage due to taking medicine in Western medicine group,while there were no adverse reac-tions in Chinese and Western medicine group.Conclusion Quzhuo Tongbi formula(祛浊通痹方)combined with febuxostat has definite clinical efficacy and good safety in the treatment of gout during intermission period,and it plays a positive role in preventing recurrence.关键词
中药复方/痛风/脾虚湿阻型/非布司他/中西医结合/病例对照研究Key words
Chinese herbal compound/Gout/Spleen deficiency-dampness obstruction pattern/Febuxostat/Inte-grative medicine/Case-control study分类
医药卫生引用本文复制引用
李美霏,张婧雅,时玮蔓,张祎,谢志军,黄继勇,温成平,周东海,王俏..祛浊通痹方联合非布司他治疗痛风间歇期的队列研究[J].中国骨伤,2025,38(12):1194-1200,7.基金项目
国家重点研发计划项目中医药现代化研究专项(编号:2022YFC3501204) （编号:2022YFC3501204）
2023年度尖兵领雁攻关项目(编号:2023C03040)Special Project on Modernization Research of Traditional Chinese Medicine Under the National Key Research and Development Program(No.2022YFC3501204) （编号:2023C03040）
